BrassicasterolCAS# 474-67-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 474-67-9 | SDF | Download SDF |
PubChem ID | 5281327 | Appearance | Cryst. |
Formula | C28H46O | M.Wt | 398.66 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | ||
SMILES | CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C | ||
Standard InChIKey | OILXMJHPFNGGTO-ZAUYPBDWSA-N | ||
Standard InChI | InChI=1S/C28H46O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-9,18-20,22-26,29H,10-17H2,1-6H3/b8-7+/t19-,20+,22-,23-,24+,25-,26-,27-,28+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Brassicasterol may be a relevant additional biomarker in Alzheimer's disease (AD). |
Brassicasterol Dilution Calculator
Brassicasterol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5084 mL | 12.542 mL | 25.084 mL | 50.1681 mL | 62.7101 mL |
5 mM | 0.5017 mL | 2.5084 mL | 5.0168 mL | 10.0336 mL | 12.542 mL |
10 mM | 0.2508 mL | 1.2542 mL | 2.5084 mL | 5.0168 mL | 6.271 mL |
50 mM | 0.0502 mL | 0.2508 mL | 0.5017 mL | 1.0034 mL | 1.2542 mL |
100 mM | 0.0251 mL | 0.1254 mL | 0.2508 mL | 0.5017 mL | 0.6271 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Campesterol
Catalog No.:BCN3181
CAS No.:474-62-4
- Campestanol
Catalog No.:BCN3890
CAS No.:474-60-2
- Daucosterol
Catalog No.:BCN5531
CAS No.:474-58-8
- Reserpin N-oxide
Catalog No.:BCN3493
CAS No.:474-48-6
- Citrostadienol
Catalog No.:BCN7357
CAS No.:474-40-8
- Chenodeoxycholic acid
Catalog No.:BCN2620
CAS No.:474-25-9
- Brazilin
Catalog No.:BCN5529
CAS No.:474-07-7
- Forskolin G
Catalog No.:BCN5527
CAS No.:473981-11-2
- Lersivirine
Catalog No.:BCC1698
CAS No.:473921-12-9
- Boc-Tyr(tBu)-OH
Catalog No.:BCC3462
CAS No.:47375-34-8
- SCH 563705
Catalog No.:BCC1933
CAS No.:473728-58-4
- SCH 527123
Catalog No.:BCC1932
CAS No.:473727-83-2
- CAL-130 Racemate
Catalog No.:BCC1442
CAS No.:474012-90-3
- N-Methylsarpagine methosalt
Catalog No.:BCN5530
CAS No.:47418-70-2
- Monomethyl auristatin E
Catalog No.:BCC1775
CAS No.:474645-27-7
- 2,16-Kauranediol 2-O-beta-D-allopyranoside
Catalog No.:BCN1436
CAS No.:474893-07-7
- ST 91
Catalog No.:BCC7436
CAS No.:4749-61-5
- SB 657510
Catalog No.:BCC7713
CAS No.:474960-44-6
- H-N-Me-Pro-OH
Catalog No.:BCC3351
CAS No.:475-11-6
- (+)-Isocorynoline
Catalog No.:BCN2361
CAS No.:475-67-2
- Liriodenine
Catalog No.:BCN5532
CAS No.:475-75-2
- Aristolochic acid B
Catalog No.:BCN6263
CAS No.:475-80-9
- Glaucine
Catalog No.:BCN2550
CAS No.:475-81-0
- Nuciferine
Catalog No.:BCN1223
CAS No.:475-83-2
Sterol lipid metabolism in down syndrome revisited: down syndrome is associated with a selective reduction in serum brassicasterol levels.[Pubmed:22649448]
Curr Gerontol Geriatr Res. 2012;2012:179318.
Over the past 15 years, insights into sterol metabolism have improved our understanding of the relationship between lipids and common conditions such as atherosclerosis and Alzheimer's Disease (AD). A better understanding of sterol lipid metabolism in individuals with Down Syndrome (DS) may help elucidate how this population's unique metabolic characteristics influence their risks for atherosclerosis and AD. To revisit the question of whether sterol lipid parameters may be altered in DS subjects, we performed a pilot study to assess traditional serum sterol lipids and lipoproteins, as well as markers of sterol biosynthesis, metabolites, and plant sterols in 20 subjects with DS compared to age-matched controls. Here we report that the levels of nearly all lipids and lipoproteins examined are similar to control subjects, suggesting that trisomy 21 does not lead to pronounced general alterations in sterol lipid metabolism. However, the levels of serum Brassicasterol were markedly reduced in DS subjects.